Stoke Therapeutics (STOK) Gains from Investment Securities (2018 - 2026)
Stoke Therapeutics' quarterly Gains from Investment Securities came in at $1.3 million in Q1 2026, down 31.54% year-on-year from $2.0 million in Q1 2025, and down 88.82% quarter-over-quarter from $12.0 million in Q4 2025.
Stoke Therapeutics has reported Gains from Investment Securities for 9 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 31.54% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 31.54% YoY), and the FY2025 full-year result was $868987.0, down 89.13% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $1.3 million, down from $12.0 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $12.0 million in Q4 2025, with the low at $79400.0 in Q3 2022.
- Average Gains from Investment Securities over 5 years is $2.2 million, with a median of $998356.0 recorded in 2024.
- Year-over-year, Gains from Investment Securities slumped 93.65% in 2022 and jumped 657.01% in 2024.
- Tracing STOK's Gains from Investment Securities over 5 years: stood at $3.5 million in 2022, then plunged by 97.22% to $96340.0 in 2023, then soared by 8197.96% to $8.0 million in 2024, then surged by 50.01% to $12.0 million in 2025, then tumbled by 88.82% to $1.3 million in 2026.
- The last three Gains from Investment Securities figures came in at $1.3 million (Q1 2026), $12.0 million (Q4 2025), and $809300.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.34 Mn |
| Mar 31, 2026 | 1.34 Mn |
| Dec 31, 2025 | 11.99 Mn |
| Dec 31, 2025 | 11.99 Mn |
| Sep 30, 2025 | 809,300.00 |
| Sep 30, 2025 | 809,300.00 |
| Jun 30, 2025 | 407,482.00 |
| Jun 30, 2025 | 407,482.00 |
| Mar 31, 2025 | 1.96 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 7.99 Mn |
| Dec 31, 2024 | 7.99 Mn |
| Sep 30, 2024 | 729,300.00 |
| Sep 30, 2024 | 729,300.00 |
| Jun 30, 2024 | 897,712.00 |
| Jun 30, 2024 | 897,712.00 |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Sep 30, 2023 | 96,340.00 |
| Sep 30, 2023 | 96,340.00 |
| Jun 30, 2023 | 281,587.00 |
| Jun 30, 2023 | 281,587.00 |
| Mar 31, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Sep 30, 2022 | 79,400.00 |
| Sep 30, 2022 | 79,400.00 |
| Jun 30, 2022 | 360,400.00 |
| Jun 30, 2022 | 360,400.00 |
| Mar 31, 2022 | 2.06 Mn |
| Mar 31, 2022 | 2.06 Mn |
| Sep 30, 2021 | 1.25 Mn |
| Sep 30, 2021 | 1.25 Mn |
| Jun 30, 2021 | 1.19 Mn |
| Jun 30, 2021 | 1.19 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Dec 31, 2020 | 27.30 Mn |
| Dec 31, 2020 | 27.30 Mn |
| Sep 30, 2020 | 168,255.00 |
| Sep 30, 2020 | 168,255.00 |
| Jun 30, 2020 | 114,990.00 |
| Jun 30, 2020 | 114,990.00 |
| Mar 31, 2020 | 2.15 Mn |
| Mar 31, 2020 | 2.15 Mn |
| Sep 30, 2019 | 1.07 Mn |
| Sep 30, 2019 | 1.07 Mn |
| Jun 30, 2019 | 3.15 Mn |
| Jun 30, 2019 | 3.15 Mn |
| Mar 31, 2019 | -3,000.00 |
| Mar 31, 2019 | -3,000.00 |
| Dec 31, 2018 | 3.48 Mn |
| Dec 31, 2018 | 3.48 Mn |